Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa   Highlights: Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy First prospective clinical study in advanced ... Read More